Tatyana A. Shubina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tatyana A. Shubina has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ludmila A. Lyapina
Department of Biology, Moscow State University, Moscow, Russia
18 shared publications - Tamara Y. Obergan
Faculty of Biology, Moscow State University, Moscow, Russia
15 shared publications L. A. Andreeva
Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia
11 shared publicationsN. F. Myasoedov
Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia
10 shared publicationsV. E. Pastorova
M. V. Lomonosov State Moscow University
5 shared publicationsM. E. Grigor’EVa
Faculty of Biology
4 shared publications
Latest Publications
- 1 March 2025
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 80 (1) , 31-39
The Corrective Effect of Chitosan on Hemostasis Parameters under Hypocoagulation Conditions Caused by the Antiplatelet Agent Clopidogrel
The effect of chitosan in vitro on the blood plasma of healthy rats and rats with acquired bleeding caused by the use of the antiplatelet agent clopidogrel
- 1 March 2025
- Published by Allerton Press in Moscow University Biological Sciences Bulletin
- Vol. 80 (1) , 31-39
The Corrective Effect of Chitosan on Hemostasis Parameters under Hypocoagulation Conditions Caused by the Antiplatelet Agent Clopidogrel
The effect of chitosan in vitro on the blood plasma of healthy rats and rats with acquired bleeding caused by the use of the antiplatelet agent clopidogrel
- Open Access
- 12 December 2022
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»
- Vol. 66 (4) , 20-26
Effect of a chitosan composite with aspartic acid on the change in reactions of the hemostasis system in experimental hypocoagulation
Введение. Геморрагические состояния, обусловленные нарушением реакций сосудисто-тромбоцитарного и/или плазменного гемостаза при бактериальных инфекциях, воспалении и травмах различного генеза являются серьезной проблемой физиологии и медицины. Представляет интерес использование биополимеров на основе хитозана, обладающих высокой гемостатической активностью. Цель работы - исследование действия композита хитозана с аспарагиновой кислотой, а также его составных компонентов на противосвертывающий потенциал плазмы крови животных с экспериментальной гипокоагуляцией. Методика. Исследование выполнено на 48 крысах-самцах Wistar, разделенных на 5 групп. Композит хитозана (100 мг/кг) с аспарагиновой кислотой (2 мг/кг), его составные части в дозах, эквивалентных их содержанию в композите или физиологический раствор (контроль) вводили крысам перорально ежедневно 1 раз в сутки в течение 14 сут. Для моделирования экспериментальной гипокоагуляции через 10 мин после введения исследуемых препаратов животные 1-й - 4-й групп получали ацетилсалициловую кислоту (1,5 мг/кг, перорально). Группу 5-ю составили интактные крысы. Через 20 ч после завершения курса введения в плазме крови животных оценивали АДФ-стимулированную агрегацию тромбоцитов, показатели плазменного гемостаза (АЧТВ, протромбиновое время, тромбиновое время, содержание фибриногена, активность фактора свертывания FXIIIa) и фибринолитическую активность (суммарную, ферментативную и фибриндеполимеризационную). Результаты. Применение композита хитозана с аспарагиновой кислотой способствовало повышению гемостатического потенциала крови, что выражалось в снижении всех видов фибринолитической активности плазмы крови, ускорении времени свертывания (по АЧТВ и протромбиновому времени), возрастании активности фактора FXIIIa и содержания фибриногена, а также в увеличении агрегации тромбоцитов. Отдельно хитозан также вызывал усиление свертываемости крови животных, но в меньшей степени, чем композит, а аспарагиновая кислота оказывала влияние только на ферментативный фибринолиз и агрегацию тромбоцитов. Заключение. Полученные данные свидетельствуют о высокой эффективности композита хитозана с аспарагиновой кислотой в качестве средства, нормализующего сосудисто-тромбоцитарный и плазменный гемостаз при гипокоагуляционных состояниях. Background. Hemorrhagic conditions caused by impaired reactions of vascular-platelet and/or plasma hemostasis in bacterial infections, inflammation and injuries of various origin are a serious challenge to physiology and medicine. It seems promising to use chitosan-based biopolymers with a high hemostatic activity.the aim of the study was to investigate the effect of a chitosan composite with aspartic acid and its components on the anticlotting potential of blood plasma from animals with experimental hypocoagulation.methods. The study was performed on 48 male Wistar rats divided into 5 groups. The chitosan (100 mg/kg) composite with aspartic acid (2 mg/kg), its components at doses equivalent to their content in the composite, or a saline (control) were administered orally to rats daily once a day daily for 14 days. To simulate experimental hypocoagulation, 10 min after the drug administration, animals of groups 1-4 received acetylsalicylic acid (1.5 mg/kg, orally). Group 5 consisted of intact rats. ADP-stimulated platelet aggregation, plasma hemostasis parameters (APTT, prothrombin time, thrombin time, fibrinogen content, coagulation factor FXIIIa activity) and fibrinolytic activity (total, enzymatic, and fibrin-depolymerization) were evaluated in the blood plasma 20 hours after completion of the course of drug administration.results. The chitosan composite with aspartic acid contributed to the increase in the blood hemostatic potential evident as a decrease in all types of plasma fibrinolytic activity, acceleration of clotting (according to APTT and prothrombin time), increased factor FXIIIa activity and fibrinogen content, as well as increased platelet aggregation. Chitosan alone also facilitated blood clotting, although to a lesser...
- 12 December 2022
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»
- Vol. 66 (4) , 20-26
Open AccessEffect of a chitosan composite with aspartic acid on the change in reactions of the hemostasis system in experimental hypocoagulation
Введение. Геморрагические состояния, обусловленные нарушением реакций сосудисто-тромбоцитарного и/или плазменного гемостаза при бактериальных инфекциях, воспалении и травмах различного генеза являются серьезной проблемой физиологии и медицины. Представляет интерес использование биополимеров на основе хитозана, обладающих высокой гемостатической активностью. Цель работы - исследование действия композита хитозана с аспарагиновой кислотой, а также его составных компонентов на противосвертывающий потенциал плазмы крови животных с экспериментальной гипокоагуляцией. Методика. Исследование выполнено на 48 крысах-самцах Wistar, разделенных на 5 групп. Композит хитозана (100 мг/кг) с аспарагиновой кислотой (2 мг/кг), его составные части в дозах, эквивалентных их содержанию в композите или физиологический раствор (контроль) вводили крысам перорально ежедневно 1 раз в сутки в течение 14 сут. Для моделирования экспериментальной гипокоагуляции через 10 мин после введения исследуемых препаратов животные 1-й - 4-й групп получали ацетилсалициловую кислоту (1,5 мг/кг, перорально). Группу 5-ю составили интактные крысы. Через 20 ч после завершения курса введения в плазме крови животных оценивали АДФ-стимулированную агрегацию тромбоцитов, показатели плазменного гемостаза (АЧТВ, протромбиновое время, тромбиновое время, содержание фибриногена, активность фактора свертывания FXIIIa) и фибринолитическую активность (суммарную, ферментативную и фибриндеполимеризационную). Результаты. Применение композита хитозана с аспарагиновой кислотой способствовало повышению гемостатического потенциала крови, что выражалось в снижении всех видов фибринолитической активности плазмы крови, ускорении времени свертывания (по АЧТВ и протромбиновому времени), возрастании активности фактора FXIIIa и содержания фибриногена, а также в увеличении агрегации тромбоцитов. Отдельно хитозан также вызывал усиление свертываемости крови животных, но в меньшей степени, чем композит, а аспарагиновая кислота оказывала влияние только на ферментативный фибринолиз и агрегацию тромбоцитов. Заключение. Полученные данные свидетельствуют о высокой эффективности композита хитозана с аспарагиновой кислотой в качестве средства, нормализующего сосудисто-тромбоцитарный и плазменный гемостаз при гипокоагуляционных состояниях. Background. Hemorrhagic conditions caused by impaired reactions of vascular-platelet and/or plasma hemostasis in bacterial infections, inflammation and injuries of various origin are a serious challenge to physiology and medicine. It seems promising to use chitosan-based biopolymers with a high hemostatic activity.the aim of the study was to investigate the effect of a chitosan composite with aspartic acid and its components on the anticlotting potential of blood plasma from animals with experimental hypocoagulation.methods. The study was performed on 48 male Wistar rats divided into 5 groups. The chitosan (100 mg/kg) composite with aspartic acid (2 mg/kg), its components at doses equivalent to their content in the composite, or a saline (control) were administered orally to rats daily once a day daily for 14 days. To simulate experimental hypocoagulation, 10 min after the drug administration, animals of groups 1-4 received acetylsalicylic acid (1.5 mg/kg, orally). Group 5 consisted of intact rats. ADP-stimulated platelet aggregation, plasma hemostasis parameters (APTT, prothrombin time, thrombin time, fibrinogen content, coagulation factor FXIIIa activity) and fibrinolytic activity (total, enzymatic, and fibrin-depolymerization) were evaluated in the blood plasma 20 hours after completion of the course of drug administration.results. The chitosan composite with aspartic acid contributed to the increase in the blood hemostatic potential evident as a decrease in all types of plasma fibrinolytic activity, acceleration of clotting (according to APTT and prothrombin time), increased factor FXIIIa activity and fibrinogen content, as well as increased platelet aggregation. Chitosan alone also facilitated blood clotting, although to a lesser...
- 27 November 2019
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 168 (2) , 250-253
Effect of a New Synthetic Peptide Preparation AСTH15-18PGP on the Hemostasis System in Rats
We studied the effect of chronic intranasal and peroral administration of a new peptide preparation AСTH15-18PGP in a dose of 100 mg/kg body weight on the state of vascular-platelet and plasma hemostasis in animals. It was found that this synthetic regulatory peptide administered intranasally can produce antiplatelet, anticoagulant, and antifibrin-stabilizing effects on the blood plasma in healthy rats. In both administration routes, the peptide induced activation of the anticoagulation system of the hemostasis by increasing enzymatic and non-enzymatic fibrinolysis; after intranasal administration, the fibrinolytic effects were more pronounced.
- 27 November 2019
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 168 (2) , 250-253
Effect of a New Synthetic Peptide Preparation AСTH15-18PGP on the Hemostasis System in Rats
We studied the effect of chronic intranasal and peroral administration of a new peptide preparation AСTH15-18PGP in a dose of 100 mg/kg body weight on the state of vascular-platelet and plasma hemostasis in animals. It was found that this synthetic regulatory peptide administered intranasally can produce antiplatelet, anticoagulant, and antifibrin-stabilizing effects on the blood plasma in healthy rats. In both administration routes, the peptide induced activation of the anticoagulation system of the hemostasis by increasing enzymatic and non-enzymatic fibrinolysis; after intranasal administration, the fibrinolytic effects were more pronounced.
- Open Access
- 1 January 2018
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in International Journal of Applied and Fundamental Research (Международный журнал прикладных и фундаментальных исследований)
- No. №10 2018,p. 106-110
INFLUENCE ARGININEMIA OLIGOPEPTIDES IN THE PRIMARY AND PLASMA HEMOSTASIS WHEN ADMINISTERED ORALLY TO HEALTHY ANIMALS
- 1 January 2018
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in International Journal of Applied and Fundamental Research (Международный журнал прикладных и фундаментальных исследований)
- No. №10 2018,p. 106-110
Open AccessINFLUENCE ARGININEMIA OLIGOPEPTIDES IN THE PRIMARY AND PLASMA HEMOSTASIS WHEN ADMINISTERED ORALLY TO HEALTHY ANIMALS
- 1 January 2018
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
- Vol. 12 (1) , 66-72
Short Oxoproline-Containing Peptides as Potential Pharmacological Means of Hypolipidemic and Antithrombotic Actions
The search and research of pharmacological agents that could combine lipid-lowering and antithrombotic effects on the human organism are one of the most urgent and important tasks of modern...
- 1 January 2018
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
- Vol. 12 (1) , 66-72
Short Oxoproline-Containing Peptides as Potential Pharmacological Means of Hypolipidemic and Antithrombotic Actions
The search and research of pharmacological agents that could combine lipid-lowering and antithrombotic effects on the human organism are one of the most urgent and important tasks of modern...
- 10 November 2017
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 3(72),p. 57-62
REGULATION OF HEMOSTASIS FUNCTIONS BY GLYPROLIN PEPTIDES AT METABOLIC SYNDROME IN RATS
Цель исследования: изучение влияния регуляторных пептидов глипролинового ряда на состояние системы гемостаза в условиях in vivo на модели крыс с экспериментальным метаболическим синдромом (МС). Материалы и методы. Эксперимент проводили на 60 беспородных белых крысах-самцах с массой тела 200±10 г в возрасте 2 месяца к началу опыта (к началу кормления высококалорийным рационом — ВКР). Развитие экспериментального МС у животных вызывали содержанием их на ВКР с избыточным содержанием углеводов и насыщенных жиров. Исследовали влияние интраназального многократного (7 раз) введения в малых дозах (50 мкг/кг) регуляторных пептидов Pro-Leu-Pro, Pro-Leu-Pro-Ala, Pro-Gly-Pro-Ala и Phe-Pro-Leu-Pro-Ala животным с МС на систему свертывания крови и фибринолиз. Результаты. Через 20 часов после последнего введения пептидов наблюдалось усиление антикоагулянтной и суммарной фибринолитической активности плазмы, обусловленной как повышением неферментативного, так и ферментативного фибринолиза плазмы, а также снижение агрегации тромбоцитов. Все исследованные пептиды обладали пролонгированным действием и способностью активировать функцию противосвертывающей системы. Заключение. Максимальный противосвертывающий эффект проявляли два пептида — Pro-Leu-Pro-Ala и Phe-Pro-Leu-Pro-Ala, причем в период после отмены их применения достоверность и значимость их эффектов возрастали. Aim: to study the eff ect of glyproline regulatory peptides on hemostasis in vivo in the model of experimental metabolic syndrome (MS) in rats. Materials and methods. The experiment was carried at 60 outbred white male rats with a body weight of 200±10 g and 2 months age at the beginning of the experiment (at the beginning of feeding with a high caloric diet — HCD). The development of experimental MC in animals was caused by HCD with an excess of carbohydrates and saturated fats. We examined the effects of intranasal repeated (7 times) administration of regulatory peptides Pro-Leu-Pro, Pro-Leu-Pro-Ala, Pro-Gly-Pro-Ala and Phe-Pro-Leu-Pro-Ala in low doses (50 μg/kg) on blood coagulation and fibrinolysis in animals with MC. Results. We revealed the enhancement of anticoagulant blood activity and total fibrinolytic activity caused by increasing of non-enzymatic and enzymatic fibrinolysis, and decreasing of platelet aggregation 20 hours after the last peptides administration. All studied peptides had prolonged action and the ability to activate anticoagulant system. Conclusion. Peptides Pro-Leu-Pro-Ala and Phe-Pro-Leu-Pro-Ala showed the maximum anticoagulant effect, and after stopping of their application the reliability and signifi cance of their effects increased.
- 10 November 2017
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 3(72),p. 57-62
REGULATION OF HEMOSTASIS FUNCTIONS BY GLYPROLIN PEPTIDES AT METABOLIC SYNDROME IN RATS
Цель исследования: изучение влияния регуляторных пептидов глипролинового ряда на состояние системы гемостаза в условиях in vivo на модели крыс с экспериментальным метаболическим синдромом (МС). Материалы и методы. Эксперимент проводили на 60 беспородных белых крысах-самцах с массой тела 200±10 г в возрасте 2 месяца к началу опыта (к началу кормления высококалорийным рационом — ВКР). Развитие экспериментального МС у животных вызывали содержанием их на ВКР с избыточным содержанием углеводов и насыщенных жиров. Исследовали влияние интраназального многократного (7 раз) введения в малых дозах (50 мкг/кг) регуляторных пептидов Pro-Leu-Pro, Pro-Leu-Pro-Ala, Pro-Gly-Pro-Ala и Phe-Pro-Leu-Pro-Ala животным с МС на систему свертывания крови и фибринолиз. Результаты. Через 20 часов после последнего введения пептидов наблюдалось усиление антикоагулянтной и суммарной фибринолитической активности плазмы, обусловленной как повышением неферментативного, так и ферментативного фибринолиза плазмы, а также снижение агрегации тромбоцитов. Все исследованные пептиды обладали пролонгированным действием и способностью активировать функцию противосвертывающей системы. Заключение. Максимальный противосвертывающий эффект проявляли два пептида — Pro-Leu-Pro-Ala и Phe-Pro-Leu-Pro-Ala, причем в период после отмены их применения достоверность и значимость их эффектов возрастали. Aim: to study the eff ect of glyproline regulatory peptides on hemostasis in vivo in the model of experimental metabolic syndrome (MS) in rats. Materials and methods. The experiment was carried at 60 outbred white male rats with a body weight of 200±10 g and 2 months age at the beginning of the experiment (at the beginning of feeding with a high caloric diet — HCD). The development of experimental MC in animals was caused by HCD with an excess of carbohydrates and saturated fats. We examined the effects of intranasal repeated (7 times) administration of regulatory peptides Pro-Leu-Pro, Pro-Leu-Pro-Ala, Pro-Gly-Pro-Ala and Phe-Pro-Leu-Pro-Ala in low doses (50 μg/kg) on blood coagulation and fibrinolysis in animals with MC. Results. We revealed the enhancement of anticoagulant blood activity and total fibrinolytic activity caused by increasing of non-enzymatic and enzymatic fibrinolysis, and decreasing of platelet aggregation 20 hours after the last peptides administration. All studied peptides had prolonged action and the ability to activate anticoagulant system. Conclusion. Peptides Pro-Leu-Pro-Ala and Phe-Pro-Leu-Pro-Ala showed the maximum anticoagulant effect, and after stopping of their application the reliability and signifi cance of their effects increased.
- 1 November 2017
- Published by Institute of Biochemistry in Biomeditsinskaya Khimiya
- Vol. 63 (6) , 546-552
Oxoprolinic short peptides – potential pharmacological means of hypolidemic and antitrombotic actions
One of the most urgent and important tasks of modern biological and medical research is the search and research of pharmacological agents that combine lipid-lowering and antithrombotic effects in the organism. The unique effects of the regulatory peptides of the oxoproline series (5-oхo-Pro-His-Pro-NH2, 5-oxo-Pro-Trp-Pro and 5-oxo-Pro-Arg-Pro or 5-oхo-Pro-His-Pro-NH2, Pyr-Trp-Pro and Pyr-Arg-Pro) have been found in rats with hypercholesterolemia (metabolic syndrome). Multiple intranasal of these peptides to animals with developed hypercholesterolemia increased anticoagulant, fibrinolytic and antiplatelet potential of the blood and simultaneously lowered increased concentrations of total cholesterol, low-density lipoprotein cholesterol and triglycerides. In addition, they contributed to the normalization of blood glucose levels. A week after the last admistration of these peptides, the hypocholesterolemic, normoglycemic and anticoagulant effects persisted. The relationship between the structure of peptides of the oxoproline series and their functional properties is discussed. A conclusion is made about the prospects of further studies of oxoproline peptides as drugs that combine antithrombotic effects with the improvement of fat metabolism in the body.
- 1 November 2017
- Published by Institute of Biochemistry in Biomeditsinskaya Khimiya
- Vol. 63 (6) , 546-552
Oxoprolinic short peptides – potential pharmacological means of hypolidemic and antitrombotic actions
One of the most urgent and important tasks of modern biological and medical research is the search and research of pharmacological agents that combine lipid-lowering and antithrombotic effects in the organism. The unique effects of the regulatory peptides of the oxoproline series (5-oхo-Pro-His-Pro-NH2, 5-oxo-Pro-Trp-Pro and 5-oxo-Pro-Arg-Pro or 5-oхo-Pro-His-Pro-NH2, Pyr-Trp-Pro and Pyr-Arg-Pro) have been found in rats with hypercholesterolemia (metabolic syndrome). Multiple intranasal of these peptides to animals with developed hypercholesterolemia increased anticoagulant, fibrinolytic and antiplatelet potential of the blood and simultaneously lowered increased concentrations of total cholesterol, low-density lipoprotein cholesterol and triglycerides. In addition, they contributed to the normalization of blood glucose levels. A week after the last admistration of these peptides, the hypocholesterolemic, normoglycemic and anticoagulant effects persisted. The relationship between the structure of peptides of the oxoproline series and their functional properties is discussed. A conclusion is made about the prospects of further studies of oxoproline peptides as drugs that combine antithrombotic effects with the improvement of fat metabolism in the body.
- 19 November 2015
- Published by Pleiades Publishing Ltd in Biology Bulletin
- Vol. 42 (6) , 546-555
Peptide regulation of metabolic processes under hypercholesterinemia conditions of an organism
The participation of short glyproline peptides in regulating the metabolic processes of the body has been established. Experimental hypercholesterolemia and the development of metabolic syndrome in...
- 19 November 2015
- Published by Pleiades Publishing Ltd in Biology Bulletin
- Vol. 42 (6) , 546-555
Peptide regulation of metabolic processes under hypercholesterinemia conditions of an organism
The participation of short glyproline peptides in regulating the metabolic processes of the body has been established. Experimental hypercholesterolemia and the development of metabolic syndrome in...
- 19 November 2015
- Published by Elsevier in Pathophysiology
- Vol. 23 (1) , 27-33
Mechanisms for glyproline protection in hypercholesterolemia
- 19 November 2015
- Published by Elsevier in Pathophysiology
- Vol. 23 (1) , 27-33
Mechanisms for glyproline protection in hypercholesterolemia
- 19 November 2014
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 158 (1) , 30-33
Hypoglycemic and Anticoagulant Effects of Tetrapeptide Pro-Gly-Pro-Leu in Hypercholesterolemia
- 19 November 2014
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 158 (1) , 30-33
Hypoglycemic and Anticoagulant Effects of Tetrapeptide Pro-Gly-Pro-Leu in Hypercholesterolemia